Objective-CD40 ligand is a thromboinflammatory molecule that predicts cardiovascular events. Platelets constitute the major source of soluble CD40 ligand (sCD40L), which has been shown to influence platelet activation, although its exact functional impact on platelets and the underlying mechanisms remain undefined. We aimed to determine the impact and the signaling mechanisms of sCD40L on platelets. Methods and Results-sCD40L strongly enhances platelet activation and aggregation. Human platelets treated with a mutated form of sCD40L that does not bind CD40, and CD40 Ϫ/Ϫ mouse platelets failed to elicit such responses. Furthermore, sCD40L stimulation induces the association of the tumor necrosis factor receptor-associated factor-2 with platelet CD40. Notably, sCD40L primes platelets through activation of the small GTPase Rac1 and its downstream target p38 mitogen-activated protein kinase, which leads to platelet shape change and actin polymerization. Moreover, sCD40L exacerbates thrombus formation and leukocyte infiltration in wild-type mice but not in CD40 Ϫ/Ϫ mice. Conclusion-sCD40L enhances agonist-induced platelet activation and aggregation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway. Thus, sCD40L is an important platelet primer predisposing platelets to enhanced thrombus formation in response to vascular injury. This may explain the link between circulating levels of sCD40L and cardiovascular diseases. (Arterioscler Thromb Vasc Biol. 2010;30:2424-2433.)
M ultiple lines of evidence now support a plethora of inflammatory mediators potentially involved in the pathogenesis of vascular disease. Among these, the CD40 ligand (CD40L)/CD40 dyad has been the focus of much attention, and circulating levels of soluble CD40L (sCD40L) are now considered reliable predictors of cardiovascular events. [1] [2] [3] [4] CD40L is a 48-kDa trimeric transmembrane protein belonging to the tumor necrosis factor superfamily originally identified on cells of the immune system. 5, 6 Interaction of CD40L with its respective receptor on B cells, CD40, a 39-kDa glycoprotein from the tumor necrosis factor receptor family, is of critical importance for immunoglobulin isotype switching during the immune response. 7 Today, we know that these 2 molecules are also present on cells of the vascular system, including endothelial cells, monocytes/macrophages, smooth muscle cells, and platelets, 8, 9 and have important implications in inflammatory reactions, through upregulation of cell adhesion molecules and production of proinflammatory cytokines, chemokines, growth factors, matrix metalloproteinases, and procoagulants. 8,10 -12 The involvement of the CD40L/CD40 dyad in thromboinflammation has been highlighted in all pathogenic phases of atherosclerosis, including endothelial dysfunction, platelet activation, thrombosis, and neointima formation. [13] [14] [15] [16] [17] [18] [19] [20] Platelets are highly specialized blood cells of paramount importance in normal hemostasis and thromboinflammatory complications. The pioneering work of Henn et al showed that both CD40L and its receptor CD40 are found in platelets. 8 Whereas CD40 is constitutively expressed on platelets, CD40L rapidly appears on the platelet surface following Figure 1 . sCD40L enhances platelet activation and aggregation through interaction with CD40. A, Dose-dependent effect of sCD40L on platelet aggregation. Platelets were preincubated with the indicated concentrations of sCD40L for 30 minutes at 37°C, and aggregation was induced by a priming dose of collagen (0.25 g/mL). Upper aggregation traces show the effect of sCD40L alone (1 g/mL). Histogram represents the mean of data of platelet aggregation in response to sCD40L alone (no agonist) or in the presence of a priming (low) dose of collagen (0.25 g/mL), thrombin (0.02 U/mL), or ADP (5 mol/L). High doses of agonists (5 g/mL collagen, 0.5 U/mL thrombin, or 20 mol/L ADP) were used as positive controls (nϭ5; *PϽ0.05 versus low dose). B, Effect of sCD40L on P-selectin (CD62P) expression and ␣ IIb ␤ 3 activation, as assessed by flow cytometry. Left plots represent resting platelets (Ϫcollagen: gray for baseline, black for sCD40L). Right plots represent platelets in the presence of a priming concentration of collagen (ϩcollagen: gray for activation, on which it is subsequently cleaved, generating a soluble fragment of 18-kDa, termed sCD40L, accounting for Ͼ95% of its plasmatic concentration. 21 Circulating levels of sCD40L in patients have now emerged as strong indicators of cardiovascular risk, as there appears to be a significant correlation between levels of sCD40L and vascular complications such as atherosclerosis and acute coronary syndromes (ACS). [2] [3] [4] Although the presence of the CD40L/CD40 dyad in platelets is well defined, its exact involvement in platelet function remains elusive. Andre et al have shown that CD40L binds to ␣ IIb ␤ 3 and stabilizes arterial thrombi in mice, 13 whereas others have shown that CD40L can induce platelet activation and secretion of reactive oxygen species and the chemokine RANTES through binding of CD40. 14, 17, 22 Nevertheless, the physiological impact and the mechanisms involved in CD40L-induced platelet activation are poorly characterized. Here we show that sCD40L primes and enhances agonistinduced activation and aggregation of human platelets through a CD40-mediated tumor necrosis factor receptorassociated factor (TRAF)-2/Rac1/p38 mitogen-activated protein kinase (MAPK)-dependent pathway, which ultimately leads to platelet shape change and actin polymerization. Moreover, we show that enhanced levels of sCD40L exacerbate thrombus formation and leukocyte infiltration in response to vascular injury, in a CD40-dependent manner.
Materials and Methods
An expanded Methods section is available in the supplemental materials, available online at http://atvb.ahajournals.org.
This study has been approved by the human and animal ethical committees of the Montreal Heart Institute. All human subjects gave informed consent and were free from drugs interfering with platelet function. This study was conducted with washed human platelets and platelets from wild-type (WT) and CD40 Ϫ/Ϫ mice. Platelet aggregation was assessed optically, and activation was determined by flow cytometry. We used a commercial form of sCD40L (R&D Systems), as well as a recombinant mutated form of sCD40L that does not recognize CD40 (sCD40L R/Y ), and its WT counterpart. Expression of TRAFs in total platelet lysates and in CD40 immunoprecipitates was determined by SDS-PAGE. Platelet shape change and actin polymerization were analyzed by scanning electron and confocal microscopy, respectively. Rac1 activation was assessed by a p21activated kinase 1-p21 binding domain (PAK1-PBD) pull-down assay of its GTP-bound form, and vasodilator-stimulated phosphoprotein (VASP) and p38 MAPK activation were measured by SDS-PAGE using specific antibodies against the phosphorylated form of VASP on Ser157 and p38 MAPK on Thr180/Tyr182. In vivo thrombosis was measured in a FeCl 3 -induced carotid injury model in WT and CD40 Ϫ/Ϫ mice. Leukocyte incorporation at the sites of injury was measured by CD45 immunostaining of thrombus sections.
Results sCD40L Enhances Platelet Activation and Aggregation Through Interaction With CD40
We first evaluated the functional effects of sCD40L on platelet activation and aggregation, as it remains poorly characterized. Incubation of platelets with sCD40L alone had no effect on platelet aggregation ( Figure 1A , upper panel) but led to a significant and dose-dependent increase of platelet aggregation induced by a subthreshold or priming concentration of collagen, thrombin, or ADP ( Figure 1A) , indicating that this is a broad platelet phenomenon and not agonistspecific. As sCD40L showed a significant impact on platelet aggregation, we sought to determine its effect on platelet activation. As expected, sCD40L was unable to trigger activation of ␣ IIb ␤ 3 on resting platelets, whereas it caused a significant increase in P-selectin expression ( Figure 1B ). However, ␣ IIb ␤ 3 activation and P-selectin expression were both significantly enhanced in the presence of subthreshold concentrations of collagen, thrombin, and ADP.
Because it has been shown that ␣ IIb ␤ 3 , in addition to CD40, can constitute a CD40L receptor on the platelet surface, 13, 23 it was imperative to investigate through which receptor sCD40L acts. To address this issue, we first generated a mutant recombinant sCD40L (sCD40L R/Y ) that does not bind CD40 while retaining ␣ IIb ␤ 3 binding (Supplemental Figure I ) and showed that this molecule failed to enhance platelet aggregation induced by a priming concentration of collagen, compared with its WT counterpart (sCD40L WT ) ( Figure 1C ). Second, unlike platelets from WT mice, platelets from CD40 Ϫ/Ϫ mice were insensitive to mouse sCD40L in response to a subthreshold concentration of collagen ( Figure  1D ). These data clearly show that sCD40L enhances platelet function through interaction with its counterreceptor CD40.
sCD40L Triggers TRAF-2 Association With CD40
It is well established that the TRAF family is tightly linked to CD40 signaling in immune cells. The TRAF family comprises 6 known members, among which TRAF-1, -2, -3, and -6 have been the most studied, although their expression in platelets is yet to be determined. We therefore investigated the expression of the major TRAF members and their association with CD40 on sCD40L stimulation. Interestingly, we found that in addition to CD40, platelets express TRAF-1, -2, and -6, and traces of TRAF-3 were detected ( Figure 2A ). Most importantly, only TRAF-2 associates with CD40 after stimulation of resting platelets with sCD40L, whereas none of these members were shown to be associated with CD40 at Figure 1 (Continued) . priming dose of collagen, black for priming dose ϩ sCD40L, and white for high-dose collagen alone, as positive control). Histograms represent the mean of data of plots for CD62P expression and ␣ IIb ␤ 3 activation in response to sCD40L alone (no agonist) or in the presence of a priming (low) dose of collagen (1 g/mL), thrombin (0.02 U/mL), or ADP (5 mol/L). High doses of agonists (5 g/mL collagen, 0.5 U/mL thrombin, or 20 mol/L ADP) were used as positive controls (nϭ5; †PϽ0.05 versus baseline and *PϽ0.05 versus low dose). C, Effect of recombinant mutant sCD40L R/Y and sCD40L WT on human platelet aggregation. Platelets were incubated with 1 g/mL of sCD40L R/Y or sCD40L WT for 30 minutes at 37°C and aggregation was induced by a priming dose of collagen (0.25 g/mL). sCD40L was used as a positive control. D, Effect of mouse (m) sCD40L on WT and CD40 Ϫ/Ϫ mouse platelet aggregation. Platelets were incubated with msCD40L (1 g/mL) for 30 minutes at 37°C, and aggregation was induced by a priming concentration of collagen (1 g/mL). Data in parentheses shown in C and D represent the meanϮSEM of nϭ4.
baseline conditions (Figure 2A and 2B ). In addition, sCD40L WT , but not sCD40L R/Y , caused association of TRAF-2, further supporting the contribution of CD40 in response to sCD40L.
sCD40L Induces Platelet Shape Change and Actin Polymerization
In search of the underlying cellular and molecular events involved in the effects of sCD40L on platelet function, we first found that stimulation of resting platelets with sCD40L caused a significant morphological shape change characterized by an increase in lamellipodia and filopodia formation ( Figure 3A) . Second, sCD40L induced actin polymerization, as noted by the increase in F-actin staining in treated platelets ( Figure 3B ). To determine the implication of these cytoskeletal and morphological changes in sCD40L-induced potentiation of platelet aggregation, we pretreated platelets with latrunculin B, a specific inhibitor of actin polymerization, and found that it completely reversed sCD40L's capacity to increase platelet aggregation ( Figure 3C and 3D).
The Small GTPase Rac1 and p38 MAPK Are Required for sCD40L Signaling
The Rho family GTPase member Rac1 and the VASP represent key signaling components required for cytoskeletal reorganization and shape change in platelets. Phosphorylation of VASP, particularly at Ser157, regulates its anticapping activity and thereby promotes platelet filopodia formation. 24 As shown in Figure 4A , stimulation of resting platelets with sCD40L, but not with sCD40L R/Y , induced phosphorylation of VASP on Ser157 and activation of Rac1. To assess the implication of the small GTPase Rac1, we used a specific Rac1 inhibitor, NSC23766. Pretreatment of platelets with NSC23766 significantly reversed sCD40L's ability to enhance platelet aggregation ( Figure 4B ) and P-selectin expression ( Figure 4C ) in resting platelets.
Activation of p38 MAPK is of significant importance in CD40 signaling, and in platelets it could therefore act as a downstream target of Rac1 in response to sCD40L. In fact, sCD40L induced a time-dependent activation of p38 MAPK, and inhibition of Rac1 with NSC23766 significantly reduced its activation, indicating that p38 MAPK does indeed act as a downstream target of Rac1 ( Figure 5A ). Furthermore, specific blockade of p38 MAPK with SB203580, which prevented its phosphorylation (Supplemental Figure II) , impaired the effects of sCD40L on platelet P-selectin expression ( Figure 5B ) and aggregation ( Figure 5C ), thus highlighting its implication in these responses. These data establish Rac1 and its downstream effector p38 MAPK as key components involved in sCD40L signaling in platelets.
sCD40L Exacerbates Thrombus Formation and Leukocyte Infiltration
To date, no direct correlation between circulating levels of sCD40L and thrombosis has been established, and this could be of important clinical and physiopathological relevance. To explore this aspect, we injected sCD40L (0.25 mg/kg or approximately 5 g/mouse) into WT and CD40 Ϫ/Ϫ mice before vascular injury, thereby enhancing its plasma circulating levels to 47.5Ϯ3.7 ng/mL (nϭ4), and assessed thrombus formation. Infusion of sCD40L into WT mice significantly exacerbated thrombus formation, in comparison with vehicletreated mice, in which occlusion was only partial ( Figure 6 ). Interestingly, CD40 Ϫ/Ϫ mice were protected from increased A, Representative blots of lysates from resting (baseline) or sCD40L (1 g/mL)-stimulated platelets immunoprecipitated using an anti-CD40 monoclonal antibody and analyzed by SDS-PAGE for TRAF-1, -2, -3, and -6. B, Histogram represents the mean of data of blots in A, expressed as arbitrary units of optical density (nϭ5; *PϽ0.05 versus baseline). C, CD40 was immunoprecipitated from lysates of resting (baseline) or 1 g/mL of sCD40L R/Y or sCD40L WT stimulated platelets. Immunoprecipitates were then analyzed by SDS-PAGE for TRAF-2. Blot shown is representative of 4 independent experiments. levels of circulating sCD40L, as no significant difference in thrombosis between treated and nontreated groups was observed ( Figure 6A and 6B) , confirming the in vivo contribution of the CD40 receptor in sCD40L-induced thrombus formation. Because sCD40L induces surface expression of P-selectin on platelets ( Figure 1B) , we sought to determine the extent of leukocyte infiltration within the thrombus because of its involvement in platelet/leukocyte interactions, a well-established aspect of hemostasis known to potentiate thrombus formation. 25 Leukocyte infiltration, as measured by CD45 immunostaining ( Figure 6C ) and optical quantification of histological sections postthrombosis ( Figure 6D) , was significantly increased in WT but not in CD40 Ϫ/Ϫ mice that received sCD40L. These results establish a direct in vivo correlation between circulating levels of sCD40L and arterial thrombosis, while highlighting the requirement of the CD40 receptor in this process.
Discussion
CD40L has gained much attention over the years for its involvement in the pathogenesis of atherosclerosis, and to-day, numerous clinical studies show a tight association between levels of sCD40L and vascular diseases. [1] [2] [3] [4] The majority of sCD40L found in plasma is believed to originate from activated platelets, and this in turn has been shown to influence platelet activation. Here, we provide novel insights into the regulation of platelet function by CD40L, as we show that sCD40L primes platelets and enhances aggregation through a CD40-mediated TRAF-2/Rac1/p38 MAPKdependent pathway. This ultimately leads to shape change and actin polymerization. Furthermore, we establish a direct correlation between circulating levels of sCD40L and thrombus formation.
To get insights into the cellular and molecular impact of sCD40L on platelet function, it was important that we first investigate its effect on platelet aggregation and activation. sCD40L was unable to trigger aggregation of resting platelets or to induce activation of the integrin ␣ IIb ␤ 3 , whereas it significantly increased the expression of P-selectin, in accordance with previous studies. 14, 17, 22 This may be attributed to the fact that sCD40L alone does not affect intraplatelet calcium 4 . The Rho-GTPase Rac1 is required for sCD40L signaling. A, VASP phosphorylation and Rac1 activation were detected from platelets left untreated (baseline) or incubated with sCD40L (1 g/mL) for the indicated time. Control experiments were performed in parallel with 1 g/mL of sCD40L R/Y and sCD40L WT after 30 minutes stimulation. Blots are representative of 4 independent experiments. B, Effect of Rac1 inhibition on sCD40L-induced potentiation of platelet aggregation. Platelets were preincubated with the Rac1 inhibitor NSC23766 (50 mol/L) or vehicle dimethyl sulfoxide for 15 minutes at 37°C. Cells were then left unstimulated (control) or incubated with sCD40L (1 g/mL). Aggregation was then monitored in the presence of a priming dose of collagen (0.25 g/mL). Histogram represents the mean of data of aggregation traces (nϭ4; *PϽ0.05 versus sCD40L). C, Platelets were left untreated (baseline) or incubated with sCD40L (1 g/mL) with or without NSC23766 (50 mol/L) and assessed by flow cytometry for CD62P expression. Histogram shows the mean data of overlay plot (nϭ3; *PϽ0.05 versus sCD40L). Figure III) or dense granule secretion, as assessed by ATP release and mepacrine uptake (Supplemental Figure IV) , which are necessary for integrin activation and platelet aggregation. However, we found that sCD40L strongly enhanced platelet aggregation, P-selectin expression, and ␣ IIb ␤ 3 activation in response to subthreshold concentrations of platelet agonists, indicating that it rather acts as a broad and potent primer of platelets, such as matrix metalloproteinase-2, plasma protein growth arrest-specific 6, and stromal derived factor-1␣. 26 -28 Moreover, this priming phenomenon holds true for B cell proliferation, as sCD40L requires costimulation with interleukin-4 for immunoglobulin E secretion. 29, 30 Taken together, this would indicate that CD40L acts as an accessory, but important, element in platelet function.
influx (Supplemental
One important aspect of controversy regards the identification of the platelet receptor for sCD40L. In our study, we were able to show by molecular and genetic approaches that sCD40L enhances platelet function by interacting with CD40. These results are in agreement with previously published data showing that sCD40L can induce platelet activation and secretion of reactive oxygen species and the chemokine RANTES through binding to CD40. 14, 17, 22 In addition to CD40, its constitutively expressed receptor on platelets, it has been reported that sCD40L binds to ␣ IIb ␤ 3 . 13, 23 However, this occurs in the presence of 40 g/mL of rsCD40L on preactivated platelets (␣ IIb ␤ 3 already in its active form), which is 40 times higher than the concentration used in the present study. This may suggest that CD40 and ␣ IIb ␤ 3 constitute the high- Figure 5 . The p38 MAPK is an important Rac1 downstream target in response to sCD40L. A, Platelets were left untreated (time 0) or stimulated with sCD40L (1 g/mL), with or without NSC23766 (50 mol/L), for the indicated time and assessed for p38 MAPK phosphorylation by SDS-PAGE. Results are expressed as fold increase in optical density (O.D.) over time 0 (nϭ4; *PϽ0.05). B, Platelets were left unstimulated (baseline) or incubated with sCD40L (1 g/mL), with or without the p38 MAPK inhibitor SB203580 (5 mol/L) and assessed for CD62P by flow cytometry. Histogram represents the mean of data of overlay plot (nϭ5; *PϽ0.05 versus sCD40L). C, Platelets were preincubated with SB203580 (5 mol/L) or vehicle dimethyl sulfoxide for 15 minutes at 37°C. Cells were then left unstimulated (control) or incubated with sCD40L (1 g/mL), and aggregation was then induced by a priming dose of collagen (0.25 g/mL). Histogram represents the mean of data of aggregation traces (nϭ4; *PϽ0.05 versus sCD40L). p-p38 indicates phosphorylated p38. and low-affinity receptors for sCD40L, respectively. However, additional studies are necessary to specifically address this issue. Thus, it appears that increased levels of circulating sCD40L, as seen in ACS patients, prime platelets via CD40, whereas its interaction with ␣ IIb ␤ 3 at the site of vascular injury, where higher levels of sCD40L may be generated, stabilizes platelet aggregates.
CD40 signaling in immune and endothelial cells requires its association to TRAF proteins. To our knowledge, the expression of TRAF members in platelets and their association with platelet CD40 following sCD40L stimulation are still unknown. Here, we found that only TRAF-2 associates with CD40 on ligation, indicating that it may be responsible for sCD40L/CD40-induced signaling in platelets. Although they are present in platelets, neither TRAF-1 nor TRAF-6 associate with CD40, indicating that they may instead play a role in tumor necrosis factor signaling. Even though CD40 contains binding sites for both TRAF-2 and TRAF-6, binding of either one is sufficient to induce activation of nuclear factor-B in B cells. 31 This would also hold true for platelets, as binding of TRAF-2 alone appears sufficient to trigger downstream signaling.
In platelets, Rac1 and VASP govern shape change, cytoskeletal reorganization, and spreading, through lamellipodia and filopodia formation, respectively. VASP is typically phosphorylated on 2 main residues, Ser239 and Ser157. Platelet inhibitors induce phosphorylation of both residues, whereas agonists that cause platelet activation trigger phosphorylation of VASP on Ser157, thereby promoting anticapping activity and favoring actin polymerization and filopodia formation. 32, 33 Our finding that sCD40L promotes phosphorylation of VASP on Ser157 provides evidence for its role as an inducer of shape change in platelets. As further support for the role of sCD40L in these processes, we highlight its capacity to induce activation of the small GTPase Rac1. Rac1 activation in response to sCD40L was shown to be of physiological importance, given that its specific inhibition significantly reduced sCD40L's ability to potentiate platelet aggregation and P-selectin expression. Interestingly, in accordance with our results, it has recently been shown that in endothelial and WEHI 231 B cells, CD40 signaling-induced reactive oxygen species generation requires activation of Rac1. 19, 34 Moreover, in immune cells, CD40L is classically known to induce activation of MAPKs, such as p38. Here, we were able to confirm that sCD40L induces activation of p38 MAPK in resting platelets, 17, 22 and further highlight its involvement in platelet activation and aggregation as a downstream effector of Rac1 in response to sCD40L. Consistent with its role in sCD40L-induced shape change and platelet priming, p38 MAPK has been shown to be an important regulator of actin polymerization and platelet spreading. 35 Whether enhanced levels of sCD40L seen in patients with ACS are a consequence of increased platelet activation or a predetermining cause of these complications (or perhaps both) is still unknown. Here, we provide novel evidence demonstrating a direct correlation between enhanced levels of sCD40L and thrombosis. Mice that received sCD40L before vascular injury showed increased thrombus formation, indicating that they were predisposed to thrombotic stimulus. Our study adds new insights to a previous work showing that CD40L Ϫ/Ϫ mice develop unstable thrombi and that this deficiency can be overcome by infusion of 1.6 mg/kg sCD40L in a ␣ IIb ␤ 3 -dependent manner. 13 Here, a different approach was used, as we increased circulating levels of sCD40L in mice by injecting 0.25 mg/kg to reach approximately 50 ng/mL of plasma sCD40L, to mimic conditions similar to those seen in patients with ACS. In this experimental setting, sCD40L was shown to exacerbate thrombosis in WT mice but not in CD40 Ϫ/Ϫ mice, indicating that enhanced levels of sCD40L prime resting platelets in a CD40dependent manner, predisposing them to enhanced thrombus formation. Because CD40 Ϫ/Ϫ mice do not show a defect in thrombus formation, it is likely that CD40 is not essential for platelet hemostasis in the absence of significant levels of sCD40L but rather has a pathological importance in atherothrombosis in the presence of elevated levels of circulating sCD40L as seen in patients with ACS. Given that sCD40L induces platelet P-selectin expression, which is involved in platelet/leukocyte interactions 14, 17, 20 and stabilization of thrombus mass, 25 we measured the extent of leukocyte infiltration within the thrombus. We found significantly more leukocytes within the thrombus of sCD40L-treated mice, presumably accounting for the increase in thrombus formation seen in these animals, concomitantly with enhanced platelet predisposition to activation and aggregation in response to vascular injury.
Elevated levels of sCD40L are associated with increased cardiovascular risk, as seen in patients with ACS, such as unstable angina 36 and acute myocardial infarction. 3 However, the relative importance of the soluble form versus the membrane-bound form in thrombus formation is still unknown. It is likely that both forms are involved in primary hemostasis, whereas under pathological conditions, thrombosis is exacerbated by increased levels of the soluble form. Nevertheless, the involvement of CD40L in atherogenesis, thrombus formation, platelet-mediated inflammation, and plaque destabilization makes it a potential therapeutic target in atherothrombosis. Accordingly, it would be pertinent for future clinical studies to evaluate the degree of platelet priming in ACS patients, specifically through sCD40Linduced TRAF-2 association with CD40, for instance. Hence, a direct clinical link between sCD40L and platelet function could be established for pharmacological targeting.
In summary, aside from this newly identified TRAF-2/ Rac1/p38 MAPK pathway involved in platelet priming in response to sCD40L, we highlight the relevance of sCD40L in a physiopathological setting of platelet function and thrombus formation. Indeed, enhanced levels of sCD40L potentiate platelet aggregation and exacerbate thrombus formation and leukocyte infiltration in response to vascular injury, in a CD40-dependent manner. This study provides novel evidence for the regulation of platelet function by sCD40L and may partly explain the link between levels of circulating sCD40L and the occurrence of cardiovascular complications. The CD40L/CD40 axis may ultimately represent a therapeutic target in the treatment of thromboinflammatory diseases.
